Drug Profile

Bardoxolone methyl - Biogen

Alternative Names: Bard - Biogen; Bardoxolone methyl - Abbott/Kyowa Hakko Kirin/Biogen; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
Developer Biogen; Kyowa Kirin; University of Texas M. D. Anderson Cancer Center
Class Anti-inflammatories; Antihypertensives; Antineoplastics; Antivirals; Carboxylic acids; Hepatoprotectants; Nitriles; Obesity therapies; Small molecules; Triterpenes; Urologics
Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF-E2-related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hereditary nephritis; Pancreatic cancer; Autosomal dominant polycystic kidney disease; Pulmonary arterial hypertension
New Molecular Entity Yes

Discontinued Autosomal dominant polycystic kidney disease; COVID 2019 infections; Diabetic nephropathies; Haematological malignancies; Hereditary nephritis; Liver disorders; Malignant melanoma; Non-alcoholic steatohepatitis; Obesity; Pancreatic cancer; Pulmonary arterial hypertension; Pulmonary hypertension; Renal failure; Solid tumours; Viral hepatitis

26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in Australia (PO)
05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in France (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com